Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Sales

ProQR Therapeutics (PRQR) Debt to Equity (2014 - 2025)

ProQR Therapeutics recorded quarterly Debt to Equity of $0.1 in Q4 2025, up 90.72% quarter-over-quarter from $0.05 in Q4 2024, and up 90.72% year-over-year from $0.05 in Q4 2024.

ProQR Therapeutics' Debt to Equity history runs 12 years deep, the most recent figure standing at $0.1 for Q4 2025.

  • In Q4 2025, Debt to Equity rose 90.72% year-over-year to $0.1; the TTM figure through Dec 2025 stood at $0.1 (up 90.72% YoY), while the FY2025 annual figure was $0.1, up 90.72% from the prior year.
  • Debt to Equity came in at $0.1 for Q4 2025 at ProQR Therapeutics, up from $0.05 in the prior quarter.
  • In the past five years, Debt to Equity ranged from a high of $0.43 in Q2 2022 to a low of $0.05 in Q4 2024.
  • A 5-year average of $0.17 and a median of $0.1 in 2022 frame the typical range for Debt to Equity.
  • Across the five-year window, Debt to Equity surged 200.89% in 2022 and slumped 84.04% in 2023, its largest moves.
  • ProQR Therapeutics' Debt to Equity stood at $0.39 in 2021, then plunged by 73.72% to $0.1 in 2022, then advanced by 2.12% to $0.1 in 2023, then slumped by 50.11% to $0.05 in 2024, then soared by 90.72% to $0.1 in 2025.
  • According to Business Quant data, Debt to Equity over the past three periods registered $0.1, $0.05, and $0.1 for Q4 2025, Q4 2024, and Q4 2023 respectively.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Debt/Equity (Qtr)
1 Quantum Biopharma 961,148.99 Bn 961,148.98 Bn - -
2 Alterity Therapeutics 744,933.29 Bn 744,933.26 Bn - -
3 Legend Biotech 2,540.00 Bn 2,539.71 Bn 242.10 Mn -
4 Nanobiotix 2,199.85 Bn 2,199.78 Bn - -
5 Akari Therapeutics 1,635.88 Bn 1,635.88 Bn - -
6 Vertex Pharmaceuticals 111.32 Bn 104.07 Bn 2.59 Bn -
7 Evaxion A 62.56 Bn 62.54 Bn - -
8 Regeneron Pharmaceuticals 62.55 Bn 53.79 Bn 3.31 Bn 0.06
9 Alnylam Pharmaceuticals 39.57 Bn 36.56 Bn 959.66 Mn -
10 ProQR Therapeutics 174.11 Mn 66.54 Mn - 0.10

Historic Data

Download Data 🔒
DateValue
Dec 31, 2025 0.10
Dec 31, 2024 0.05
Dec 31, 2023 0.10
Sep 30, 2023 0.06
Jun 30, 2023 0.07
Mar 31, 2023 0.07
Dec 31, 2022 0.10
Sep 30, 2022 0.07
Jun 30, 2022 0.43
Mar 31, 2022 0.38
Dec 31, 2021 0.39
Sep 30, 2021 0.14
Jun 30, 2021 0.14
Mar 31, 2021 0.33
Dec 31, 2020 0.31
Sep 30, 2020 0.24
Jun 30, 2020 0.06
Mar 31, 2020 0.16
Dec 31, 2019 0.14
Sep 30, 2019 0.18
Jun 30, 2019 0.15
Mar 31, 2019 1.17
Dec 31, 2018 0.10
Sep 30, 2018 0.06
Jun 30, 2018 0.26
Mar 31, 2018 0.19
Dec 31, 2017 0.18
Dec 31, 2016 0.11
Dec 31, 2015 0.00
Dec 31, 2014 0.03